GPC3 and hepatocellular carcinoma: As for ACT, encompassing the utilization of transgenic tumor antigen specific TCR-T or CAR-T, it is noteworthy that, to date, clinical benefits have exclusively been observed in advanced HCC patients through the application of CAR-T cells engineered to target Glypican-3 (GPC3) [10].